Understanding the biological role of MGMT promotor status and its clinical impact in the presence of TERT promotor mutations and absence of IDH mutations in gliomas formerly assigned to WHO grade II and III may be of great importance for future therapeutic management of such patients. The gene discussed is TERT; the disease is central nervous system cancer.